Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05624723
Other study ID # INCB054707-106
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date January 12, 2023
Est. completion date February 7, 2024

Study information

Verified date February 2024
Source Incyte Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multi-center, open-label, parallel-group study to evaluate oral doses of INCB054707 in participants with varying levels of renal function or impairment.


Other known NCT identifiers
  • NCT05694195

Recruitment information / eligibility

Status Completed
Enrollment 43
Est. completion date February 7, 2024
Est. primary completion date February 7, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 82 Years
Eligibility Inclusion Criteria: - Classification at screening by renal function based on eGFR as calculated by the MDRD formula and requirement for HD (Group 5). - Participants eligible for Group 5 with ESRD have received HD for at least 3 months prior to screening. - Participants eligible for Group 1 should be in good health as determined by no clinically significant deviations from normal for medical history, physical examination, vital signs, 12-lead ECGs, or clinical laboratory determinations at screening or Day -1. - Participants eligible for Groups 2 through 5 may have medical findings consistent with their degree of renal dysfunction, as determined by medical history, physical examination, vital signs, 12-lead ECGs, and clinical laboratory determinations at screening and Day -1 (Groups 2 through 4) or Period 1 Day -1 (Group 5). - Body mass index within the range of 18.0 to 40.0 kg/m2 (inclusive) at screening. - Willingness to avoid pregnancy or fathering children Exclusion Criteria: - History of uncontrolled or unstable cardiovascular, respiratory, hepatic, GI, endocrine, hematopoietic, psychiatric, and/or neurological disease within 6 months of screening or evidence of rapidly deteriorating renal function. - Current, functioning organ transplant or a cheduled organ transplant within 6 weeks after check-in. - History of malignancy within 5 years of screening, with the exception of cured basal cell carcinoma, squamous cell carcinoma of the skin, ductal carcinoma in situ, or Gleason 6 prostate cancer. - History of clinically significant GI disease or surgery (cholecystectomy and appendectomy are allowed) that could impact the absorption of study drug. - Eligible for Group 1 and have a history of renal disease or renal injury as indicated by an abnormal, clinically significant renal function profile at screening or Day -1. - Eligible for Groups 2 through 5 and have had a change in disease status within 30 days of screening, as documented by the participant's medical history and deemed clinically significant by the investigator. - History or current diagnosis of uncontrolled or significant cardiac disease indicating significant risk of safety for participation in the study, including any of the following: 1. Recent myocardial infarction (within 6 months of check-in) 2. New York Heart Association Class III or IV congestive heart failure 3. Unstable angina (within 6 months of check-in) 4. Clinically significant (symptomatic) cardiac arrhythmias (eg, sustained ventricular tachycardia, second- or third-degree atrioventricular block without a pacemaker) 5. Uncontrolled hypertension - Any major surgery within 4 weeks of screening. - Donation of blood to a blood bank within 4 weeks of screening (within 2 weeks for plasma only). - Blood transfusion within 4 weeks of Day -1 (for Groups 1 through 4) or Period 1 Day -1 (Group 5). - Chronic or current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment. - Positive test and symptomatic for HBV, HCV, or HIV. Participants whose results are compatible with prior immunization for or immunity due to infection with HBV may be included at the discretion of the investigator. - Eligible for Group 1 and have a history of using tobacco- or nicotine-containing products within 6 months of screening. - Eligible for Groups 2 through 5 and smoke > 10 cigarettes per day or equivalent use of other tobacco- or nicotine-containing products and are unwilling to refrain from tobacco or nicotine use on dosing days and abide by CRU restrictions. - History of alcohol dependency within 3 months of screening. - Positive breath test for ethanol or positive urine or saliva screen for drugs of abuse (confirmed by repeat test) at screening or check-in that are not otherwise explained by permitted concomitant medications. - Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) of study drug administration with another investigational medication or current enrollment in another investigational drug study. - Current treatment or treatment within 15 days or 5 half-lives (whichever is longer) before the first dose of study drug with moderate and potent inducers or inhibitors of CYP3A4 (refer to the Drug Interaction Database Program [University of Washington School of Pharmacy 2002] for prohibited drugs). - Consumption of Seville oranges, grapefruit or grapefruit juice, pomelos, exotic citrus fruits, grapefruit hybrids, or fruit juices within 72 hours before the first dose of study drug. - Eligible for Group 1 and have used prescription drugs within 14 days of study drug administration or nonprescription medications/products (including vitamins, minerals, and hytotherapeutic/herbal/plant-derived preparations) within 7 days of study drug administration. However, occasional use of acetaminophen and ibuprofen is permitted (see Section 6.6.1). - Eligible for Groups 2 through 5 and have used prescription drugs within 14 days of study drug administration, with the exception of established therapy for renal disease and the treatment of associated disorders that have been stable for at least 7 days prior to study drug administration, as approved by the investigator and in consultation with the sponsor's medical monitor. - Current or recent history (within 30 days before screening) of a clinically significant bacterial, fungal, parasitic, or mycobacterial infection, currently receiving systemic antibiotics, or having a current clinically significant viral infection at screening or check-in. - History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) deemed clinically relevant by the investigator. - Inability to undergo venipuncture or tolerate venous access. - Eligible for Group 5 and not expected to continue HD treatment for the duration of the study. - Women who are pregnant or breastfeeding. - Use of hormonal contraception - QTcF > 450 milliseconds for Groups 1 through 3 and QTcF > 470 milliseconds for Group 4. - Eligible for Group 1 and have abnormal LFT values, defined as aspartate aminotransferase, alanine aminotransferase, and serum (total and direct) bilirubin, as well as amylase and lipase above the upper limit of the normal range at screening. - Eligible for Groups 2 through 4 and have values outside the normal ranges for LFTs; however, values may be acceptable if they are consistent with the participant's renal condition (if stable for 1 month prior to screening) and if the investigator (or designee) and the sponsor feel that the results are not clinically significant (based on age and renal impairment status). - Receipt of live (including attenuated) vaccines within 3 months of check-in or anticipation of need for such a vaccine during the study (Note: Nonlive or inactivated vaccines are allowed up to 2 weeks prior to the first dose of study drug). - Known hypersensitivity or severe reaction to INCB054707 or excipients of INCB054707 (refer to the IB).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
INCB054707
INCB054707 75 mg will be administered orally

Locations

Country Name City State
Germany Apex Gmbh Munich
United States Orlando Clinical Research Center Orlando Florida

Sponsors (1)

Lead Sponsor Collaborator
Incyte Corporation

Countries where clinical trial is conducted

United States,  Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pharmacokinetics Parameter: Cmax of INCB054707 Defined as maximum observed plasma concentration of INCB054707 Days 1-4
Primary Pharmacokinetics Parameter: AUC0-t of INCB054707 Area Under the concentration- time curve up to the last measurable concentration of INCB054707 Days 1-4
Primary Pharmacokinetics Parameter: AUC0-8 of INCB54707 Defined as under the concentration-time curve up to the last measurable concentration of INCB054707 Days 1-4
Secondary Number of Treatment Emergent Adverse Events (TEAE'S) Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment. Up to 21 days
Secondary Pharmacokinetics Parameter: tmax of INCB054707 Defined as time to reach maximum plasma concentration of INCB054707; during dialysis for Group 5 Period 1. Days 1-4
Secondary Pharmacokinetics Parameter: t½ of INCB054707 Defined as apparent terminal-phase disposition half-life of INCB054707; during dialysis for Group 5 Period 1. Days 1-4
Secondary Pharmacokinetics Parameter: CL/F of INCB054707 Defined as oral dose clearance of INCB054707; during dialysis for Group 5 Period 1. Days 1-4
Secondary Pharmacokinetics Parameter: Vz/F of INCB054707 Defined as apparent oral dose volume of distribution; during dialysis for Group 5 Period 1. Days 1-4
Secondary Pharmacokinetics Parameter: AUC3-7 of INCB054707 Defined as area under the concentration-time curve from 1 to 5 of INCB054707; during dialysis for Group 5 Period 1. Days 1-4
See also
  Status Clinical Trial Phase
Completed NCT03246984 - VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ N/A
Completed NCT03545113 - Graft-first Versus Fistula-first in Older Patients With End-stage Kidney Disease N/A
Recruiting NCT05100017 - Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure N/A
Recruiting NCT04559321 - Holmium Vs Trilogy Kidney Stones GUY's 1-2 Phase 3
Recruiting NCT05036850 - China Kidney Patient Trials Network
Completed NCT04037436 - Functional Exercise and Nutrition Education Program for Older Adults N/A
Active, not recruiting NCT01529658 - Renal Hypothermia During Partial Nephrectomy N/A
Completed NCT01679587 - Dose Escalation Study to Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY85-3934 in Subjects With Chronic Kidney Disease (CKD) Phase 1
Completed NCT01155141 - Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH Phase 4
Completed NCT00755690 - Study of Dietary Phosphate and Mineral Homeostasis in Early Chronic Kidney Disease N/A
Recruiting NCT05759754 - Effects of Traditional Chinese Medicine (GSJYF) in Children With Inherited Proteinuric Kidney Disease N/A
Completed NCT03213158 - Ixazomib for Desensitization Phase 2
Active, not recruiting NCT02237352 - Mechanisms of Diabetic Nephropathy in Ecuador
Recruiting NCT06067867 - Kidney and Pregnancy Registry
Recruiting NCT04110080 - Enhanced Recovery After Surgery in Kidney Transplant Donors N/A
Active, not recruiting NCT04876963 - HOLT-ED: Holter-monitoring in End-stage Renal Disease
Enrolling by invitation NCT05324878 - Honoring Individual Goals and Hopes: Implementing Advance Care Planning for Persons With Kidney Disease on Dialysis
Not yet recruiting NCT03899298 - Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions Phase 1
Active, not recruiting NCT04631965 - Healthcare Transition of Adolescents With Chronic Health Conditions
Completed NCT03394859 - Electronic Medical Records and Genomics (eMERGE) Phase III